Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Noninvasive Genetic Prenatal Testing Possible Using Rare Fetal Cells

XTALKS VITALS NEWS

Prenatal

RareCyte’s technology is capable of detecting gene deletions between two and three million base pairs in length, which is an improvement over current technologies.

Share this!

October 26, 2016 | by Sarah Hand, M.Sc.

Rare fetal cells which can be isolated from a pregnant woman’s blood sample, could be used to develop noninvasive genetic prenatal tests. The research – which was conducted at Baylor College of Medicine and RareCyte, Inc. – was published in the journal, Prenatal Diagnosis.

“Fetal cells were first reported in the circulation of pregnant women more than 40 years ago, and people have been hoping since that time to be able to use them for prenatal diagnosis,” said senior study author Dr. Arthur Beaudet, Chair of Molecular and Human Genetics at Baylor. “With the emergence of RareCyte's platform technology for the identification of rare circulating cells and the retrieval of single cells, this is now possible.”

RareCyte, a life sciences company that offers tools able to analyze single cells from liquid biopsies and tissue samples, has developed a specialized platform capable of isolating rare fetal cells. The technology utilizes an automated image scanner to identify these fetal cells, coupled with a precision needle to extract them from the sample.

“Our goal in this project was to determine whether it was possible to collect trophoblasts present in the mother's circulation in numbers sufficient for further genetic analysis,” said Beaudet. Trophoblasts form the major part of the placenta and contain all of the genetic information from the fetus.

According to RareCyte, while two teaspoons of maternal blood contains hundreds of billions of red blood cells, only 20 to 40 fetal cells may be present in the sample. Using their imaging technology, the researchers were regularly able to extract three to 10 fetal cells which could be further analyzed using tools including next generation DNA sequencing.



“We are pleased to be working with Dr. Beaudet and his team at Baylor on this critical project,” said Ron Seubert, chairman and CEO of RareCyte. “This is a milestone achievement in prenatal research and for RareCyte.”

As certain invasive forms of prenatal testing carry risks for both mother and baby, some chose to perform noninvasive methods, including cell-free DNA testing. Unfortunately, these technologies have limitations in terms of the resolution of DNA changes that can be detected. RareCyte’s technology is capable of detecting gene deletions between two and three million base pairs in length, which is an improvement over current technologies.

The company believes that this test could offer comparable information to that obtained through amniocentesis and chorionic villus sampling. According to Beaudet, this test could be available to parents seeking prenatal diagnosis, in the next one or two years.


Keywords: Prenatal Testing, Next Generation Sequencing, Liquid Biopsy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.